News

'I do press ups every day so I can care for my son'
A mum in Monmouth describes her fears about managing her severely disabled son's care needs.
Precision Medicine Online2d
Ionis Treats First Patient in Phase III Antisense Oligonucleotide Trial in Angelman Syndrome
The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.
Clinical Trials Arena on MSN2d
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare ...